S

SCYNEXIS
D

SCYX

0.74490
USD
0.02
(2.99%)
مغلق
حجم التداول
846
الربح لكل سهم
-0
العائد الربحي
-
P/E
-1
حجم السوق
29,066,202
أصول ذات صلة
A
ACAD
-0.285
(-1.34%)
20.955 USD
A
AMRN
0.025
(0.15%)
16.665 USD
D
DVAX
0.095
(0.94%)
10.250 USD
NVS
NVS
-1.350
(-1.09%)
122.490 USD
المزيد
الأخبار المقالات

العنوان: SCYNEXIS

القطاع: Healthcare
الصناعة: Drug Manufacturers - Specialty & Generic
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.